Literature DB >> 27131830

The role of the melanoma gene MC1R in Parkinson disease and REM sleep behavior disorder.

Ziv Gan-Or1, Noreen Mohsin2, Simon L Girard3, Jacques Y Montplaisir4, Amirthagowri Ambalavanan5, Stephanie Strong2, Victoria Mallett2, Sandra B Laurent2, Cynthia V Bourassa2, Michel Boivin6, Melanie Langlois7, Isabelle Arnulf8, Birgit Högl9, Birgit Frauscher9, Christelle Monaca10, Alex Desautels11, Jean-François Gagnon12, Ronald B Postuma13, Patrick A Dion14, Yves Dauvilliers15, Nicolas Dupre7, Roy N Alcalay16, Guy A Rouleau17.   

Abstract

The MC1R gene, suggested to be involved in Parkinson disease (PD) and melanoma, was sequenced in PD patients (n = 539) and controls (n = 265) from New York, and PD patients (n = 551), rapid eye movement sleep behavior disorder (RBD) patients (n = 351), and controls (n = 956) of European ancestry. Sixty-eight MC1R variants were identified, including 7 common variants with frequency > 0.01. None of the common variants was associated with PD or RBD in the different regression models. In a meta-analysis with fixed-effect model, the p.R160W variant was associated with an increased risk for PD (odds ratio = 1.22, 95% confidence interval = 1.02-1.47, p = 0.03) but with significant heterogeneity (p = 0.048). Removing one study that introduced the heterogeneity resulted in nonsignificant association (odds ratio = 1.11, 95% confidence interval, 0.92-1.35, p = 0.27, heterogeneity p = 0.57). Rare variants had similar frequencies in patients and controls (10.54% and 10.15%, respectively, p = 0.75), and no cumulative effect of carrying more than one MC1R variant was found. The present study does not support a role for the MC1R p.R160W and other variants in susceptibility for PD or RBD.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Genetics; MC1R; Melanoma; Parkinson disease

Mesh:

Substances:

Year:  2016        PMID: 27131830      PMCID: PMC4892956          DOI: 10.1016/j.neurobiolaging.2016.03.029

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  42 in total

1.  Parkinson disease and malignant melanoma in first-degree relatives of patients with early-onset melanoma.

Authors:  Jørgen H Olsen; Thomas L Jørgensen; Kathrine Rugbjerg; Søren Friis
Journal:  Epidemiology       Date:  2011-01       Impact factor: 4.822

Review 2.  Advances in the genetics of Parkinson disease.

Authors:  Joanne Trinh; Matt Farrer
Journal:  Nat Rev Neurol       Date:  2013-07-16       Impact factor: 42.937

Review 3.  Parkinson's disease, levodopa-use and the risk of melanoma.

Authors:  J-D Vermeij; A Winogrodzka; J Trip; W E J Weber
Journal:  Parkinsonism Relat Disord       Date:  2009-06-05       Impact factor: 4.891

4.  The melanocortin 1 receptor (Mc1r) variants do not account for the co-occurrence of Parkinson's disease and malignant melanoma.

Authors:  Sandra Elincx-Benizri; Rivka Inzelberg; Lior Greenbaum; Oren S Cohen; Gilad Yahalom; Yael Laitman; Ruth Djaldetti; Yael Orlev; Alon Scope; Esther Azizi; Eitan Friedman; Sharon Hassin-Baer
Journal:  J Mol Neurosci       Date:  2014-10-05       Impact factor: 3.444

5.  Four novel rare mutations of PLA2G6 in Chinese population with Parkinson's disease.

Authors:  Ya-Xing Gui; Zhong-Ping Xu; Hong-Mei Liu; Jin-Jia Zhao; Xing-Yue Hu
Journal:  Parkinsonism Relat Disord       Date:  2012-11-20       Impact factor: 4.891

6.  Common pathogenic pathways in melanoma and Parkinson disease.

Authors:  Coro Paisán-Ruiz; Henry Houlden
Journal:  Neurology       Date:  2010-11-02       Impact factor: 9.910

7.  Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy--a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group.

Authors:  C H Schenck; J Y Montplaisir; B Frauscher; B Hogl; J-F Gagnon; R Postuma; K Sonka; P Jennum; M Partinen; I Arnulf; V Cochen de Cock; Y Dauvilliers; P-H Luppi; A Heidbreder; G Mayer; F Sixel-Döring; C Trenkwalder; M Unger; P Young; Y K Wing; L Ferini-Strambi; R Ferri; G Plazzi; M Zucconi; Y Inoue; A Iranzo; J Santamaria; C Bassetti; J C Möller; B F Boeve; Y Y Lai; M Pavlova; C Saper; P Schmidt; J M Siegel; C Singer; E St Louis; A Videnovic; W Oertel
Journal:  Sleep Med       Date:  2013-07-22       Impact factor: 4.842

8.  Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease.

Authors:  Mike A Nalls; Nathan Pankratz; Christina M Lill; Chuong B Do; Dena G Hernandez; Mohamad Saad; Anita L DeStefano; Eleanna Kara; Jose Bras; Manu Sharma; Claudia Schulte; Margaux F Keller; Sampath Arepalli; Christopher Letson; Connor Edsall; Hreinn Stefansson; Xinmin Liu; Hannah Pliner; Joseph H Lee; Rong Cheng; M Arfan Ikram; John P A Ioannidis; Georgios M Hadjigeorgiou; Joshua C Bis; Maria Martinez; Joel S Perlmutter; Alison Goate; Karen Marder; Brian Fiske; Margaret Sutherland; Georgia Xiromerisiou; Richard H Myers; Lorraine N Clark; Kari Stefansson; John A Hardy; Peter Heutink; Honglei Chen; Nicholas W Wood; Henry Houlden; Haydeh Payami; Alexis Brice; William K Scott; Thomas Gasser; Lars Bertram; Nicholas Eriksson; Tatiana Foroud; Andrew B Singleton
Journal:  Nat Genet       Date:  2014-07-27       Impact factor: 38.330

9.  Is the MC1R variant p.R160W associated with Parkinson's?

Authors:  Steven J Lubbe; Valentina Escott-Price; Alexis Brice; Thomas Gasser; John Hardy; Peter Heutink; Manu Sharma; Nicholas W Wood; Mike Nalls; Andrew B Singleton; Nigel M Williams; Huw R Morris
Journal:  Ann Neurol       Date:  2015-12-12       Impact factor: 10.422

10.  Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer.

Authors:  Gordana Maric; April An Rose; Matthew G Annis; Peter M Siegel
Journal:  Onco Targets Ther       Date:  2013-07-09       Impact factor: 4.147

View more
  6 in total

1.  The melanoma-linked "redhead" MC1R influences dopaminergic neuron survival.

Authors:  Xiqun Chen; Hongxiang Chen; Waijiao Cai; Michael Maguire; Bailiu Ya; Fuxing Zuo; Robert Logan; Hui Li; Katey Robinson; Charles R Vanderburg; Yang Yu; Yinsheng Wang; David E Fisher; Michael A Schwarzschild
Journal:  Ann Neurol       Date:  2017-01-23       Impact factor: 10.422

Review 2.  Idiopathic REM sleep behaviour disorder and neurodegeneration - an update.

Authors:  Birgit Högl; Ambra Stefani; Aleksandar Videnovic
Journal:  Nat Rev Neurol       Date:  2017-11-24       Impact factor: 42.937

3.  Overlapping genetic architecture between Parkinson disease and melanoma.

Authors:  Umber Dube; Laura Ibanez; John P Budde; Bruno A Benitez; Albert A Davis; Oscar Harari; Mark M Iles; Matthew H Law; Kevin M Brown; Carlos Cruchaga
Journal:  Acta Neuropathol       Date:  2019-12-16       Impact factor: 17.088

4.  Red hair, MC1R variants, and risk for Parkinson's disease - a meta-analysis.

Authors:  Xiqun Chen; Danielle Feng; Michael A Schwarzschild; Xiang Gao
Journal:  Ann Clin Transl Neurol       Date:  2017-02-24       Impact factor: 4.511

Review 5.  Accuracy of Rating Scales and Clinical Measures for Screening of Rapid Eye Movement Sleep Behavior Disorder and for Predicting Conversion to Parkinson's Disease and Other Synucleinopathies.

Authors:  Matej Skorvanek; Eva Feketeova; Monica M Kurtis; Jan Rusz; Karel Sonka
Journal:  Front Neurol       Date:  2018-05-25       Impact factor: 4.003

6.  Whole Exome Sequencing Study in Isolated South-Eastern Moravia (Czechia) Population Indicates Heterogenous Genetic Background for Parkinsonism Development.

Authors:  Kristyna Kolarikova; Radek Vodicka; Radek Vrtel; Julia Stellmachova; Martin Prochazka; Katerina Mensikova; Petr Kanovsky
Journal:  Front Neurosci       Date:  2022-03-17       Impact factor: 4.677

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.